CuraTeQ Biologics received Marketing Authorization for Dyrupeg™, a pegylated filgrastim biosimilar

The European Commission (EC) granted marketing authorization in the European Union (EU) for Dyrupeg™, a pegylated filgrastim biosimilar, to CuraTeQ Biologics s.r.o., a wholly owned step-down subsidiary of AUROBINDO PHARMA LIMITED. Earlier in January 2025, the Committee for Medicinal Products (CHMP) of European Medicines Agency had adopted positive opinion recommending the approval of Dyrupeg™.

Shares of Aurobindo Pharma Limited was last trading in BSE at Rs. 1104.80 as compared to the previous close of Rs. 1176.05. The total number of shares traded during the day was 205181 in over 13800 trades.

The stock hit an intraday high of Rs. 1176.60 and intraday low of 1049.85. The net turnover during the day was Rs. 224653343.00.

Source : Equity Bulls

Keywords

AurobindoPharma INE406A01037 CuraTeQBiologics MarketingAuthorization Dyrupeg Biosimilar